Skip to main content
. 2017 Sep 5;8:619. doi: 10.3389/fphar.2017.00619

FIGURE 2.

FIGURE 2

Effect of oral administration of (±)-8-ADC and SASP in DSS-induced mice (n = 6). (A) Treatment with 150 and 300 mg/kg (±)-8-ADC effectively prevented body weight loss in DSS-induced mice and had no effect in healthy mice. (B) Oral administration of (±)-8-ADC (150 and 300 mg/kg) for 7 days significantly ameliorated colon contracture in DSS-induced mice (p < 0.01). (C) Compared to the DSS group (contracture 46%), treatment with 150 and 300 mg/kg (±)-8-ADC reduced the colon contracture to 26 and 17%, respectively (p < 0.01). (D) Compared with the DSS group, all doses of orally administered (±)-8-ADC significantly decreased the DAI score. (E) Colon HE staining. Epithelial cell loss, submucosal ulceration, and a large number of infiltrating inflammatory cells were observed in the DSS-induced group. Treatment of these mice with (±)-8-ADC decreased this pathological damage in the colon tissue. (F) Colon histological scores. Treatment with (±)-8-ADC reduced the histological scores of the colons of DSS-induced mice compared to mock-treated DSS-induced mice. ##p < 0.01 compared with control group; ∗p < 0.05, ∗∗p < 0.01 compared with DSS group.